
|Videos|March 21, 2022
The role of doublet and triplet therapies in prostate cancer
Author(s)Urology Times staff
“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.
Advertisement
In this video, William K. Oh, MD, discusses the rise of doublet and triplet therapies in the treatment of prostate cancer, and what questions are still being investigated related to these novel treatments.Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Updated AUA/SUO Advanced Prostate Cancer guideline emphasizes role of PSMA-PET
2
Study links unmet social needs with worse stone-specific quality of life
3
Casdatifan shows durable activity in metastatic clear cell renal cell carcinoma
4
Matthew Truesdale, MD, on IsoPSA performance with and without mpMRI
5












